Latest Leadership News

Lovisa Holdings has appointed John Cheston as Global CEO and Managing Director, alongside Mark McInnes as Executive Deputy Chairman, signaling a strategic push for global growth.

Adveritas Limited reports a record 61% increase in annualised recurring revenue, driven by strong gains in sports betting and new product launches, while preparing for a strategic expansion into North America.

Frontier Digital Ventures announces the resignation of CEO Shaun Di Gregorio effective November 2025, with co-founder Patrick Grove stepping in as Chairman immediately.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

AdAlta Limited has successfully raised $1.1 million through a renounceable rights issue, positioning itself to advance key CAR-T licensing and immunotherapy projects. The capital injection underscores confidence from leadership and investors amid a transformative phase for the biotech company.

Mont Royal Resources has announced the appointment of Nicholas Holthouse as President and CEO of Commerce Resources, setting the stage for their upcoming merger. Holthouse's extensive rare earths expertise is expected to drive the merged entity's growth in critical minerals.

SRJ Technologies is advancing its transformation into a full-scale Asset Integrity Maintenance provider, appointing a new CEO and relocating its global headquarters to Abu Dhabi to anchor its growth in energy and industrial sectors.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

Pacific Edge has successfully raised NZ$16 million through an upsized equity placement, surpassing its initial target and setting the stage for a planned NZ$5 million Share Purchase Plan. The funds aim to accelerate clinical and commercial milestones, including regaining Medicare coverage for its cancer diagnostic tests.

IDP Education has revised its FY25 guidance, forecasting a sharp decline in student placements and language testing volumes due to persistent immigration policy uncertainty across key markets including the UK, Australia, Canada, and the US.

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

INOVIQ Limited has revealed promising data for its EXO-OC™ ovarian cancer screening test, demonstrating exceptional accuracy and flawless detection of early-stage cancers. This innovation could transform early diagnosis and treatment outcomes for women worldwide.